Cargando…

Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US

IMPORTANCE: Clinical trials and compassionate use agreements provide selected patients with access to potentially life-saving treatments before approval by the Food and Drug Administration (FDA). Approval from the FDA decreases a number of access barriers; however, it is unknown whether FDA approval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ermer, Theresa, Canavan, Maureen E., Maduka, Richard C., Li, Andrew X., Salazar, Michelle C., Kaminski, Michael F., Pichert, Matthew D., Zhan, Peter L., Mase, Vincent, Kluger, Harriet, Boffa, Daniel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247736/ https://www.ncbi.nlm.nih.gov/pubmed/35771575 http://dx.doi.org/10.1001/jamanetworkopen.2022.19535

Ejemplares similares

Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Esophageal Cancer
por: Zhan, Peter L., et al.
Publicado: (2022)

Association of Insurance Status and Extent of Organ Involvement With Survival Among Patients With Stage IV Cancer
por: Zhan, Peter L., et al.
Publicado: (2022)

Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
por: Pichert, Matthew D., et al.
Publicado: (2022)

Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer
por: Zhan, Peter Lee, et al.
Publicado: (2022)

Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
por: Pichert, Matthew D., et al.
Publicado: (2022)

Evaluation of gastroesophageal reflux disease and hiatal hernia as risk factors for lobectomy complications
por: Kaminski, Michael F., et al.
Publicado: (2022)

Assessment of a collaborative treatment model for trimodal management of esophageal cancer
por: Udelsman, Brooks V., et al.
Publicado: (2023)

The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases
por: Salazar, Michelle C., et al.
Publicado: (2021)

Chemoradiation as a nonsurgical treatment option for early-stage esophageal cancers: a retrospective cohort study
por: Pathak, Ranjan, et al.
Publicado: (2021)

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials
por: Kanapuru, Bindu, et al.
Publicado: (2022)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Time for the US food and drug administration approval of condoms for anal intercourse
por: Nguyen, Brian T., et al.
Publicado: (2019)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2021)

Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
por: Moneer, Osman, et al.
Publicado: (2021)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2023)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
por: Zuabi, Nadia, et al.
Publicado: (2016)

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
por: Liang, Fei, et al.
Publicado: (2020)

Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
por: Kaplan, Robert M., et al.
Publicado: (2023)

US Supercollider approved
Publicado: (1987)

Correction to: A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors
por: Olateju, Olajumoke A., et al.
Publicado: (2023)

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
por: Lammers, Austin, et al.
Publicado: (2017)

Systemic Immunotherapy for the Treatment of Brain Metastases
por: Cohen, Justine V., et al.
Publicado: (2016)

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
por: Modi, Natansh D., et al.
Publicado: (2022)

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
por: Parikh, Ravi B., et al.
Publicado: (2023)

The US Food and Drug Administration's tentative approval process and the global fight against HIV
por: Chahal, Harinder Singh, et al.
Publicado: (2017)

Why is AAV FVIII gene therapy not approved by the US Food and Drug Administration yet?
por: Arruda, Valder R.
Publicado: (2021)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010–2020
por: Zhang, Audrey D., et al.
Publicado: (2021)

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022)

Evaluation of Cancer Care After Medicaid Expansion Under the Affordable Care Act
por: Salazar, Michelle C., et al.
Publicado: (2020)

Access to High-Volume Hospitals for High-Risk Cancer Surgery for Racial and Ethnic Minoritized Groups
por: Salazar, Michelle C, et al.
Publicado: (2022)

Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration “Animal Rule”
por: Tsai, Chia-Wei, et al.
Publicado: (2015)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration
por: Egilman, Alexander, et al.
Publicado: (2021)

Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
por: Sachs, Rachel E., et al.
Publicado: (2021)

Outcomes of surgically managed primary lung sarcomas: a National Cancer Database analysis
por: Li, Andrew X., et al.
Publicado: (2021)

High-risk Therapeutic Devices Approved by the US Food and Drug Administration for Use in Children and Adolescents From 2016 to 2021
por: Pathak, Kavya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7sgqho3suejn4h6429mge2dfbv